STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

NVS NOVARTIS AG StockScouter® Report

4

StockScouter® Score

NOVARTIS AG, a large cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The ratio of NVS’s forward price-to-earnings multiple to its estimated growth rate is below the average of comparably-sized companies in the StockScouter universe. Positive
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for NVS. Positive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is higher than the average for comparably-sized companies in the StockScouter universe. Negative
  • The multi-period measure of relative price change and consistency is below average. Negative/Neutral

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be neutral, growth stocks will be in favor, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 20% done.
Progress: 60% done.
Low
High

Core Model Grades

B
C
D
D

Previous Ratings

6
7
7